Jie Tang

Dr. Jie Tang is an NHMRC Research Fellow (EL1) at the Monash Institute of Pharmaceutical Sciences (MIPS), Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, with additional affiliation at the Australian Institute for Bioengineering and Nanotechnology (AIBN) at University of Queensland. Based in Melbourne, Victoria, Australia, Dr. Tang leads cutting-edge research in nanomedicine and drug delivery systems.

Dr. Tang's research focuses on nanomedicine, particularly in drug delivery, cancer therapy, and vaccine development. Their work spans biomimetic nanovaccines, mRNA delivery systems, and novel nanoparticle platforms for targeted cancer immunotherapy. Recent research has emphasized machine learning-engineered nanoparticles and respiratory mucosal vaccination technologies.

Analysis of Dr. Tang's 15 most recent publications reveals a strong emphasis on mRNA vaccine delivery (4 articles), biomimetic nanovaccines (3 articles), and novel nanoparticle engineering for cancer therapy (5 articles). The research demonstrates consistent innovation in overcoming biological barriers for therapeutic delivery, with particular focus on mucosal immunity, tumor microenvironment modulation, and precision nanocarrier design.

• NHMRC Research Fellow (EL1)

Dr. Tang's research program is supported by the National Health and Medical Research Council fellowship, focusing on developing advanced nanotechnologies for therapeutic delivery. Their work bridges pharmaceutical sciences and nanotechnology to address critical challenges in cancer therapy and vaccine development, with particular emphasis on overcoming biological barriers for effective drug delivery. The research has significant translational potential for clinical applications in oncology and infectious disease.

As part of the MIPS research community at Monash University, Dr. Tang contributes to one of Australia's leading pharmaceutical research institutes, collaborating with interdisciplinary teams to advance nanomedicine and drug delivery technologies. Their work connects pharmaceutical sciences with cutting-edge nanotechnology to develop solutions for unmet medical needs.